A potent triple-action topical combination used primarily for inflammatory dermatoses complicated by fungal and/or bacterial infections. Clobetasol propionate is a super-potent (Class I) corticosteroid providing rapid anti-inflammatory and immunosuppressive effects. Miconazole nitrate is a broad-spectrum imidazole antifungal effective against dermatophytes and Candida. Neomycin sulphate is an aminoglycoside antibiotic active against common Gram-positive and Gram-negative skin pathogens, notably Staphylococcus aureus.
Adult: Apply a thin film to the affected area twice daily. Maximum duration: Usually 1-2 weeks. Maximum weekly amount: Not more than 50g per week to minimize systemic absorption.
Note: 1. Wash and dry the affected area gently. 2. Take a small amount (pea-sized for an area the size of a palm) and apply a thin, even film. 3. Rub in gently until absorbed. 4. Do not cover with occlusive dressings unless specifically instructed. 5. Wash hands after application unless hands are the treatment area. Avoid contact with eyes, nose, mouth, and mucous membranes.
The combination works via three distinct mechanisms: 1) Clobetasol suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and inhibiting cytokine release. 2) Miconazole inhibits fungal ergosterol biosynthesis by blocking 14-alpha-demethylase, damaging the fungal cell membrane. 3) Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to bactericidal activity against susceptible organisms.
Pregnancy: Category C (US FDA). Clobetasol is contraindicated, especially in first trimester. Topical corticosteroids can be absorbed in amounts sufficient to cause systemic effects. Use only if potential benefit justifies potential fetal risk. Avoid large areas or prolonged use.
Driving: No effect on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects (atrophy, HPA suppression). | Major |
| Oral Anticoagulants (Warfarin) | Miconazole (systemic) can inhibit metabolism, increasing INR. Risk with topical is low but possible with large area application. | Moderate |
| Oral Hypoglycemics (Sulfonylureas) | Miconazole may potentiate hypoglycemic effect. Risk with topical is low. | Moderate |
| Systemic Corticosteroids (e.g., Prednisolone) | Additive systemic corticosteroid effects. | Major |
| Other Aminoglycosides (e.g., Gentamicin IV) | Additive risk of ototoxicity and nephrotoxicity if neomycin is systemically absorbed. | Moderate |
Same composition (Clobetasol (0.05% w/w) + Miconazole (2% w/w) + Neomycin (0.5% w/w)), different brands: